Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DVAX Dynavax Technologies	$10.50 -4.1%	$10.60	$9.22 ▼ $14.63	$1.23B	1.09	1.49 million shs	3.70 million shs
INVA Innoviva	$20.16 +1.0%	$19.70	$16.67 ▼ $22.00	$1.27B	0.38	839,997 shs	521,177 shs
XOMA XOMA Royalty	$34.20 +4.4%	$27.20	$18.35 ▼ $35.00	$413.41M	1	46,803 shs	111,643 shs
XOMAO XOMA	$25.39 -0.7%	$25.43	$23.32 ▼ $25.87	N/A	N/A	2,945 shs	7,443 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DVAX Dynavax Technologies	0.00%	-2.69%	-5.91%	+7.14%	-7.73%
INVA Innoviva	0.00%	-3.63%	+6.55%	+6.27%	+8.68%
XOMA XOMA Royalty	0.00%	+9.02%	+32.51%	+37.63%	+17.97%
XOMAO XOMA	0.00%	-0.26%	-1.03%	+0.57%	+0.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DVAX Dynavax Technologies	4.5184 of 5 stars	3.3	2.0	0.0	4.7	3.2	1.7	1.9
INVA Innoviva	4.5193 of 5 stars	3.5	1.0	0.0	4.2	4.0	1.7	1.9
XOMA XOMA Royalty	4.2392 of 5 stars	3.3	4.0	0.0	3.0	3.2	1.7	0.6
XOMAO XOMA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DVAX Dynavax Technologies	2.50	Moderate Buy	$24.33	131.75% Upside
INVA Innoviva	3.00	Buy	$42.75	112.05% Upside
XOMA XOMA Royalty	2.67	Moderate Buy	$69.50	103.22% Upside
XOMAO XOMA	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest XOMA, XOMAO, DVAX, and INVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	DVAX Dynavax Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$32.00
8/12/2025	XOMA XOMA Royalty	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/11/2025	INVA Innoviva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $45.00
8/11/2025	INVA Innoviva	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$45.00
8/8/2025	DVAX Dynavax Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$31.00 ➝ $32.00
7/14/2025	INVA Innoviva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00
7/14/2025	INVA Innoviva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00
7/11/2025	INVA Innoviva	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$26.00
5/28/2025	XOMA XOMA Royalty	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$104.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DVAX Dynavax Technologies	$316.27M	3.89	$0.16 per share	66.31	$4.21 per share	2.49
INVA Innoviva	$358.71M	3.54	$3.43 per share	5.88	$11.34 per share	1.78
XOMA XOMA Royalty	$28.49M	14.51	N/A	N/A	$5.99 per share	5.71
XOMAO XOMA	$12.77M	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DVAX Dynavax Technologies	$27.31M	-$0.46	N/A	21.43	N/A	-16.67%	5.10%	3.00%	11/6/2025 (Estimated)
INVA Innoviva	$23.39M	$0.31	65.03	13.01	N/A	10.44%	18.67%	9.92%	11/5/2025 (Estimated)
XOMA XOMA Royalty	-$13.82M	-$1.55	N/A	N/A	N/A	-27.57%	2.63%	0.97%	11/6/2025 (Estimated)
XOMAO XOMA	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	11/5/2025 (Estimated)

Latest XOMA, XOMAO, DVAX, and INVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	XOMA XOMA Royalty	-$0.12	$0.48	+$0.60	$0.44	$9.39 million	$13.13 million
8/7/2025	Q2 2025	DVAX Dynavax Technologies	$0.12	$0.14	+$0.02	$0.14	$87.55 million	$95.44 million
8/6/2025	Q2 2025	INVA Innoviva	$0.57	$0.77	+$0.20	$0.77	$87.10 million	$100.28 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DVAX Dynavax Technologies	N/A	N/A	N/A	N/A	N/A
INVA Innoviva	N/A	N/A	N/A	N/A	N/A
XOMA XOMA Royalty	N/A	N/A	N/A	N/A	N/A
XOMAO XOMA	$2.09	8.23%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DVAX Dynavax Technologies	0.45	6.65	6.01
INVA Innoviva	0.36	2.64	2.44
XOMA XOMA Royalty	1.41	4.88	4.88
XOMAO XOMA	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DVAX Dynavax Technologies	96.96%
INVA Innoviva	99.12%
XOMA XOMA Royalty	95.92%
XOMAO XOMA	N/A

Insider Ownership

Company	Insider Ownership
DVAX Dynavax Technologies	2.98%
INVA Innoviva	2.25%
XOMA XOMA Royalty	9.10%
XOMAO XOMA	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DVAX Dynavax Technologies	350	117.27 million	113.77 million	Optionable
INVA Innoviva	100	63.02 million	61.60 million	Optionable
XOMA XOMA Royalty	10	12.09 million	10.99 million	Optionable
XOMAO XOMA	10	N/A	N/A	Not Optionable

XOMA, XOMAO, DVAX, and INVA Headlines

Recent News About These Companies

Short Interest in XOMA Co. (NASDAQ:XOMAO) Decreases By 23.1%

August 22 at 2:06 AM | americanbankingnews.com

Mural Oncology accepts XOMA takeover bid

August 21 at 6:13 AM | thepharmaletter.comT

Mural Jumps on Partnership with XOMA

August 20, 2025 | baystreet.ca

Mural Oncology To Be Acquired By Xoma Royalty

August 20, 2025 | msn.com

XOMA Royalty to Buy Mural Oncology for Up to $38.8 Million

August 20, 2025 | marketwatch.com

Xoma adds fading Mural Oncology to portfolio of struggling biotechs

August 20, 2025 | fiercebiotech.comF

XOMA (NASDAQ:XOMAO) Trading Up 0.4% - Here's Why

August 14, 2025 | americanbankingnews.com

Xoma reports Q2 EPS 44c, consensus (15c)

August 13, 2025 | msn.com

XOMA Revenue Jumps 39% in Fiscal Q2

August 13, 2025 | aol.comA

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

August 13, 2025 | finance.yahoo.com

Pharmalittle: We’re reading about Bill Gates’ women’s health pledge, a Vertex pain drug failure, and more

August 5, 2025 | statnews.comS

Promise of gamma delta bispecific antibodies prompts XOMA acquisition

August 5, 2025 | thepharmaletter.comT

Xoma Royalty to Acquire Lava Therapeutics

August 4, 2025 | marketwatch.com

Hillevax Shares Gain on Acquisition Deal with XOMA Royalty

August 4, 2025 | msn.com

Xoma Royalty to Acquire Lava Therapeutics, End Development of Lead Candidate

August 4, 2025 | precisionmedicineonline.comP

Xoma strikes deals to buy struggling biotechs HilleVax, Lava

August 4, 2025 | finance.yahoo.com

Xoma Royalty to Acquire HilleVax

August 4, 2025 | marketwatch.com

XOMA Royalty to acquire cancer drug developer LAVA Therapeutics

August 4, 2025 | msn.com

Xoma Royalty to Acquire Lava Therapeutics -- Update

August 4, 2025 | marketwatch.com

XOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last? - Nasdaq

June 26, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XOMA, XOMAO, DVAX, and INVA Company Descriptions

Dynavax Technologies NASDAQ:DVAX

$10.50 -0.45 (-4.11%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$10.54 +0.04 (+0.33%)

As of 08/22/2025 06:45 PM Eastern

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Innoviva NASDAQ:INVA

$20.16 +0.19 (+0.95%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$20.24 +0.07 (+0.37%)

As of 08/22/2025 07:16 PM Eastern

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

XOMA Royalty NASDAQ:XOMA

$34.20 +1.45 (+4.43%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$34.30 +0.10 (+0.31%)

As of 08/22/2025 04:01 PM Eastern

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

XOMA NASDAQ:XOMAO

$25.38 -0.19 (-0.72%)

Closing price 08/22/2025 03:32 PM Eastern

Extended Trading

$25.38 0.00 (0.00%)

As of 08/22/2025 04:04 PM Eastern

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time